DSP 0692
Alternative Names: DSP-0692Latest Information Update: 28 May 2022
At a glance
- Originator Sumitomo Dainippon Pharma
- Developer Sumitomo Pharma
- Class Antineoplastics
- Mechanism of Action Stearoyl-CoA desaturase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2022 No recent reports of development identified for preclinical development in Cancer in Japan
- 01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
- 29 Mar 2019 Pharmacodynamics data from preclinical studies in Cancer presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)